How I treat autoimmune hemolytic anemia
Top Cited Papers
Open Access
- 1 June 2017
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 129 (22), 2971-2979
- https://doi.org/10.1182/blood-2016-11-693689
Abstract
Autoimmune hemolytic anemia (AIHA) is an uncommon entity that presents diagnostic, prognostic and therapeutic dilemmas despite being a well-recognized entity for over 150 years. Because of significant differences in the rates of hemolysis as well as associated diseases and cause there is considerable clinical heterogeneity. In addition there is a lack of clinical trials required to refine and update standardized and evidence-based therapeutic approaches. To aid the clinician in AIHA management we present four vignettes that represent and highlight distinct clinical presentations with separate diagnostic and therapeutic pathways that we utilize in our clinical practice setting. We also review the parameters present in diagnostic testing that allows for prognostic insight and present algorithms for both diagnosis and treatment of the AIHA patient in diverse situations. This is done in the hope that this review may offer guidance in regard to personalized therapy recommendations. A section is included for the diagnosis of suspected AIHA with negative testing, a relatively infrequent but challenging situation in order to assist in the overall evaluation spectrum for these patients.This publication has 78 references indexed in Scilit:
- A multi‐centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemiaBritish Journal of Haematology, 2013
- Characterization of direct antiglobulin test‐negative autoimmune hemolytic anemia: A study of 154 casesAmerican Journal of Hematology, 2012
- New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 childrenHaematologica, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Epidemiology of autoimmune diseases in DenmarkJournal of Autoimmunity, 2007
- Cold Hemolytic SyndromeHematology, 2006
- Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood, 2005
- High-dose cyclophosphamide for refractory autoimmune hemolytic anemiaBlood, 2002
- Autoimmune hemolytic anemia: A historyTransfusion Medicine Reviews, 2000